BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gu L, Yao Q, Shen Z, He Y, Ng DM, Yang T, Chen B, Chen P, Mao F, Yu Q. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis. J Gastroenterol Hepatol 2020;35:1467-76. [PMID: 32180249 DOI: 10.1111/jgh.15036] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Choi WM, Yip TC, Wong GL, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, Cant H, Chen CH, Chen CY, Huang YH, Jin YJ, Jun DW, Kim JW, Park NH, Peng CY, Shin HP, Shin JW, Yang YH, Lim YS. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis. J Hepatol 2022:S0168-8278(22)03459-6. [PMID: 36572349 DOI: 10.1016/j.jhep.2022.12.007] [Reference Citation Analysis]
2 Tony SM, Shaaban MEA, Mohamed AIM, Abdelrahim MEA. Effect of entecavir and tenofovir disoproxil fumarate on hepatocellular carcinoma in subjects with chronic hepatitis B: a meta-analysis. Beni-Suef Univ J Basic Appl Sci 2022;11. [DOI: 10.1186/s43088-022-00294-0] [Reference Citation Analysis]
3 Yip TC, Lai JC, Liang LY, Hui VW, Wong VW, Wong GL. Risk of HCC in Patients with HBV, Role of Antiviral Treatment. Curr Hepatology Rep 2022. [DOI: 10.1007/s11901-022-00588-y] [Reference Citation Analysis]
4 Tan DJH, Ng CH, Tay PWL, Syn N, Muthiah MD, Lim WH, Tang ASP, Lim KE, Lim GEH, Tamaki N, Kim BK, Teng MLP, Fung J, Loomba R, Nguyen MH, Huang DQ. Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysis. JAMA Netw Open 2022;5:e2219407. [PMID: 35767258 DOI: 10.1001/jamanetworkopen.2022.19407] [Reference Citation Analysis]
5 Oh H, Lee HY, Kim J, Kim YJ. Systematic Review with Meta-Analysis: Comparison of the Risk of Hepatocellular Carcinoma in Antiviral-Naive Chronic Hepatitis B Patients Treated with Entecavir versus Tenofovir: The Devil in the Detail. Cancers (Basel) 2022;14:2617. [PMID: 35681596 DOI: 10.3390/cancers14112617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yuan BH, Li RH, Huo RR, Li MJ, Papatheodoridis G, Zhong JH. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis. J Gastroenterol Hepatol 2022;37:782-94. [PMID: 35080052 DOI: 10.1111/jgh.15783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Huang ZH, Lu GY, Qiu LX, Zhong GH, Huang Y, Yao XM, Liu XH, Huang SJ, Wu T, Yuan Q, Wang YB, Su YY, Zhang J, Xia NS. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis. BMC Cancer 2022;22:287. [PMID: 35300634 DOI: 10.1186/s12885-022-09413-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Choi WM, Yip TC, Lim YS, Wong GL, Kim WR. Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments. J Hepatol 2022;76:186-94. [PMID: 34592365 DOI: 10.1016/j.jhep.2021.09.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Roberts SK, Majeed A, Kemp W. Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma. Clin Liver Dis 2021;25:785-803. [PMID: 34593153 DOI: 10.1016/j.cld.2021.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Yao X, Huang S, Zhou H, Tang SH, Qin JP. Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt. World J Gastroenterol 2021; 27(30): 5088-5099 [PMID: 34497437 DOI: 10.3748/wjg.v27.i30.5088] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Lee SW, Choi J, Kim SU, Lim YS. Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma. Clin Mol Hepatol 2021;27:402-12. [PMID: 34157830 DOI: 10.3350/cmh.2021.0179] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
12 Zhang B, Zhou F, Hong J, Ng DM, Yang T, Zhou X, Jin J, Zhou F, Chen P, Xu Y. The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis. World J Surg Oncol 2021;19:182. [PMID: 34154596 DOI: 10.1186/s12957-021-02291-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
13 Nguyen MH, Atsukawa M, Ishikawa T, Yasuda S, Yokohama K, Trinh HN, Arai T, Fukunishi S, Ogawa E, Hsu YC, Maeda M, Dang H, Tseng CH, Takahashi H, Jun DW, Watanabe T, Chuma M, Nozaki A, Kawada N, Cheung R, Enomoto M, Takaguchi K, Toyoda H. Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir. Am J Gastroenterol 2021;116:1264-73. [PMID: 34074829 DOI: 10.14309/ajg.0000000000001157] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
14 Yuan J, Peng Y, Hao FB, Wang YQ, Wang CR, Zhong GC. No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis. Aging (Albany NY) 2021;13:7147-65. [PMID: 33658397 DOI: 10.18632/aging.202573] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
15 Kim BH, Park J. Antiviral Therapy in Liver Cancer. Radiotherapy of Liver Cancer 2021. [DOI: 10.1007/978-981-16-1815-4_5] [Reference Citation Analysis]
16 Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, Hai H, Thuy LTT, Hosaka T, Sezaki H, Borghi JA, Cheung R, Enomoto M, Nguyen MH. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:1039-1052. [PMID: 33007228 DOI: 10.1016/s2468-1253(20)30249-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 12.3] [Reference Citation Analysis]